EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer
Technology in Cancer Research & Treatment · 2024
DOI: 10.1177/15330338241273198 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Fei Ye und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, School of Pharmacy, Jiangsu University, Zhenjiang, China. Hauptthemen laut MEDLINE: ErbB Receptors, Lung Neoplasms, Mutation, Natural Killer T-Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jiangsu Provincial Key Research and Development Program, the National Natural Science Foundation, China.
Abstract (Originalsprache)
Background
To evaluate the efficacy and safety of allogenic CD8 + natural killer T (CD8+ NKT) immunotherapy combined with gefitinib in the treatment of advanced or metastatic EGFR mutant non-small cell lung cancer (NSCLC).
Methods
This study is prospective. The NSCLC patients with exon 19 (Ex19del) or exon 21 L858R point mutations, and response to gefitinib treatment were enrolled into the trial to be randomly assigned into the gefitinib arm and the gefitinib/NKT arm. Allogenic CD8+ NKT cells were cultured in vitro and adaptive transferred into the patients via vein in the gefitinib/NKT arm. The primary endpoint was progression-free survival (PFS). Secondary endpoint analysis included time to disease progression (TTP), overall survival (OS), levels of serum tumour markers for carcinoembryonic antigen (CEA) and alanine aminotransferase (ALT) in the blood, the response rate and safety. From July 2017 to June 2021, 19 patients were randomly assigned to the gefitinib arm (n = 8) and the gefitinib/NKT arm (n = 11).
Results
The estimated median survival PFS in the gefitinib/NKT arm was significantly longer than that of the gefitinib arm (12 months vs 7 months). Similar results were also observed for the median TTP. Moreover, the gefitinib/NKT arm had better CEA control than the gefitinib arm. Clinical grade 3 adverse reactions occurred in 64% and 39% of patients in the gefitinib/NKT arm and the gefitinib arm, respectively. The most common grade 3 adverse events in the gefitinib/NKT arm included abnormal liver function in 8 cases (73%) and diarrhoea in 1 case (9%), both of which resolved after drug intervention.
Conclusion
The PFS of EGFR-mutated advanced NSCLC treated with allogenic CD8+ NKT cells combined with gefitinib was longer than that of gefitinib alone. No obvious serious adverse reactions occurred, and the patients compliance and survival status were good.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, School of Pharmacy, Jiangsu University, Zhenjiang, China.
- Department of pharmacy, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
- Institute of Oncology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
- Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China.
- Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
- Department of Respiratory, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
ORCID-Profile: Sheng Xia
Förderung
- Jiangsu Provincial Key Research and Development Program
- the National Natural Science Foundation, China
Zitieren
APA
Ye, F., Yuan, X., Yu, W., Ma, Y., Mao, C., Li, X., Li, J., Dai, C., Qian, F., Li, J., Fan, X., Zhou, Y., Dai, D., Wang, D., Chen, D., Xia, S., & Zhang, M. (2024). EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241273198
Vancouver
Ye F, Yuan X, Yu W, Ma Y, Mao C, Li X, et al. EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241273198
BibTeX
@article{Ye2024,
author = {Ye, Fei and Yuan, Xiao and Yu, Wanjun and Ma, Yali and Mao, Chaoming and Li, Xiaoqin and Li, Jian and Dai, Chunhua and Qian, Fenhong and Li, Junrong and Fan, Xiujuan and Zhou, Yuepeng and Dai, Dongfang and Wang, Deqiang and Chen, Deyu and Xia, Sheng and Zhang, Minghui},
title = {EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer},
journal = {Technology in Cancer Research & Treatment},
year = {2024},
doi = {10.1177/15330338241273198}
}
EUVIMED